Progress in Analytical Techniques for Remogliflozin Etabonate, Vildagliptin
And Metformin Hydrochloride: A Recently, Approved FDC

Prachi      Joshi; Rajendra      Kotadiya
doi:10.2174/1573412919666221025103613
Abstract

Background: Fixed-dose combinations (FDCs) are renowned formulations that contain two or more drugs pooled in a single dosage form. Their recognition is justified due to several advantages, such as impending therapeutic efficacy, reducing the episodes of adverse drug effects, having pharmacokinetic advantages, reducing pill burden, reducing the dose of individual drugs, and decreasing drug resistance development.
Objective: Recently, an FDC tablet of remogliflozin etabonate (100 mg), vildagliptin (50 mg), and metformin HCl (500/1000 mg) has been approved for the treatment of type 2 diabetes mellitus. No analytical method has been reported thus far for this newly approved combination.
Methods: Thus, this review collected and simplified information on reported analytical techniques and physicochemical and biological properties for the above-cited FDCs. The authors have explored various authenticated scientific journals, and simplified information was presented to meet the objectives.
Results: The reported methods are spectroscopy (40%, 20% & 33%), HPTLC (10%, 14% & 20%), HPLC (50%, 49% & 41%), hyphenated techniques (Nil, 14% & 5%) and electrophoresis methods (Nil, 2% & 1%) for remogliflozin etabonate, vildagliptin and metformin HCl, respectively.
Conclusion: Such extensive data would be useful to analysts in developing an analytical method for the analysis of the recently approved FDCs.
« Previous Next »
Graphical Abstract

[1]
Mohan, V.; Mithal, A.; Joshi, S.R.; Aravind, S.R.; Chowdhury, S. Remogliflozin etabonate in the treatment of type 2 diabetes: Design, development, and place in therapy. Drug Des. Devel. Ther.,  2020, 14, 2487-2501.
 [http://dx.doi.org/10.2147/DDDT.S221093] [PMID: 32612352]

[2]
DeFronzo, R.A. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes,  2009, 58(4), 773-795.
 [http://dx.doi.org/10.2337/db09-9028] [PMID: 19336687]

[3]
Balas, B.; Baig, M.R.; Watson, C.; Dunning, B.E.; Ligueros-Saylan, M.; Wang, Y.; He, Y.L.; Darland, C.; Holst, J.J.; Deacon, C.F.; Cusi, K.; Mari, A.; Foley, J.E.; DeFronzo, R.A. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J. Clin. Endocrinol. Metab.,  2007, 92(4), 1249-1255.
 [http://dx.doi.org/10.1210/jc.2006-1882] [PMID: 17244786]

[4]
Sreedhar, D.; Subramanian, G.; Udupa, N. Combination drugs: Are they rational. Curr. Sci.,  2006, 91(4), 406.

[5]
Haak, T.; Meinicke, T.; Jones, R.; Weber, S.; Eynatten, M.; Woerle, H.J. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab.,  2012, 14(6), 565-574.
 [http://dx.doi.org/10.1111/j.1463-1326.2012.01590.x] [PMID: 22356132]

[6]
Goldstein, B.J.; Pans, M.; Rubin, C.J. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin. Ther.,  2003, 25(3), 890-903.
 [http://dx.doi.org/10.1016/S0149-2918(03)80112-1] [PMID: 12852706]

[7]
Gautam, C.S.; Saha, L. Fixed dose drug combinations (FDCs): Rational or irrational: A view point. Br. J. Clin. Pharmacol.,  2008, 65(5), 795-796.
 [http://dx.doi.org/10.1111/j.1365-2125.2007.03089.x] [PMID: 18294326]

[8]
Shah, D.; Gondalia, I.; Patel, V.; Mahajan, A.; Chhalotiya, U.K. Stability indicating liquid chromatographic method for the estimation of remogliflozin etabonate. J. Chem. Metrol.,  2020, 14(2), 125-132.
 [http://dx.doi.org/10.25135/jcm.46.20.07.1734]

[9]
Ahrén, B.; Schweizer, A.; Dejager, S.; Villhauer, E.B.; Dunning, B.E.; Foley, J.E.; Ahr, B. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes. Metab.,  2011, 13(9), 775-783.
 [http://dx.doi.org/10.1111/j.1463-1326.2011.01414.x] [PMID: 21507182]

[10]
Bell, D.S.H. Combine and conquer: Advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes. Metab.,  2013, 15(4), 291-300.
 [http://dx.doi.org/10.1111/dom.12015] [PMID: 23013323]

[11]
Bell, D.S.H. The case for combination therapy as first-line treatment for the type 2 diabetic patient. Treat. Endocrinol.,  2006, 5(3), 131-137.
 [http://dx.doi.org/10.2165/00024677-200605030-00001] [PMID: 16677055]

[12]
Blonde, L.; San Juan, Z.T.; Bolton, P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr. Pract.,  2014, 20(12), 1322-1332.
 [http://dx.doi.org/10.4158/EP14259.RA] [PMID: 25370323]

[13]
Tripathi, S.; Tiwaskar, M.; Kota, S.; Parthan, G.; Mohanasundaram, A.D.S.; Mohan, V. Need of single pill fixed-dose combination with glimepiride in management of diabetes mellitus. J. Assoc. Phys. India,  2016, 2019(67), 2-6.

[14]
Fujimori, Y.; Katsuno, K.; Nakashima, I.; Ishikawa-Takemura, Y.; Fujikura, H.; Isaji, M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther.,  2008, 327(1), 268-276.
 [http://dx.doi.org/10.1124/jpet.108.140210] [PMID: 18583547]

[15]
Sigafoos, J.F.; Bowers, G.D.; Castellino, S.; Culp, A.G.; Wagner, D.S.; Reese, M.J.; Humphreys, J.E.; Hussey, E.K.; O’Connor Semmes, R.L.; Kapur, A.; Tao, W.; Dobbins, R.L.; Polli, J.W. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: Evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab. Dispos.,  2012, 40(11), 2090-2101.
 [http://dx.doi.org/10.1124/dmd.112.047258] [PMID: 22851617]

[16]
Bhargava, B.; Sharma, S.K.; Kshirsagar, N.; Tripathi, C.; Medhi, B. REM clinical trial pharmacokinetic and dynamic. In: Minutes of IND Committee Meeting; , 2019; pp. 1-29.

[17]
Tepzz, T.; Des, P.; Courte, M.À.; La, D.C.D.E. Combination immediate/delayed release delivery system for short half life pharmaceuticals including Remogliflozin. Eur. Pat. Specif.,  2016, 1(19), 1-27.

[18]
Attimarad, M.; Elgorashe, R.E.E.; Subramaniam, R.; Islam, M.M.; Venugopala, K.N.; Nagaraja, S.; Balgoname, A.A. Development and validation of Rapid RP-HPLC and green second-derivative UV spectroscopic methods for simultaneous quantification of metformin and remogliflozin in formulation using experimental design. Separations,  2020, 7(4), 59.
 [http://dx.doi.org/10.3390/separations7040059]

[19]
Attimarad, M.; Nair, A.B.; Nagaraja, S.; Aldhubiab, B.E.; Venugopala, K.N.; Pottathil, S. Smart UV derivative spectrophotometric methods for simultaneous determination of metformin and remogliflozin: Development, validation and application to the formulation. Indian J. Pharm. Edu. Res.,  2021, 55(1s), s293-s302.
 [http://dx.doi.org/10.5530/ijper.55.1s.62]

[20]
Itigimatha, N.; Chadchan, K.; Yallur, B.C. Simple and sensitive Rp-Hplc and Uv spectroscopic methods for the determination of remogliflozin etabonate in pure and pharmaceutical formulations. Turkish J. Pharm. Sci.,  2021, 2021, 55381.
 [http://dx.doi.org/10.4274/tjps.galenos.2021.55381]

[21]
El-Bagary, R.I.; Elkady, E.F.; Ayoub, B.M. Spectrophotometric methods for the determination of sitagliptin and vildagliptin in bulk and dosage forms. Int. J. Biomed. Sci.,  2011, 7(1), 55-61.
 [PMID: 23675221]

[22]
Mudaliar, S.; Armstrong, D.A.; Mavian, A.A.; O’Connor-Semmes, R.; Mydlow, P.K.; Ye, J.; Hussey, E.K.; Nunez, D.J.; Henry, R.R.; Dobbins, R.L. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care,  2012, 35(11), 2198-2200.
 [http://dx.doi.org/10.2337/dc12-0508] [PMID: 23011728]

[23]
Hilliard, M.E.; Weissberg-Benchell, J.; Hood, K.K. Psychometric properties of a diabetes resilience measure for adolescents. Diabetes,  2014, 63, A324.

[24]
Wang-Lakshman, L.; Mendonza, A.E.; Huber, R.; Walles, M.; He, Y.; Jarugula, V. Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans. Xenobiotica,  2021, 51(4), 413-426.
 [http://dx.doi.org/10.1080/00498254.2020.1867331] [PMID: 33413022]

[25]
Patle, K.; Bhowmick, M.; Rathi, J. Formulation and evaluation of monolithic matrix transdermal therapeutic system of vildagliptin using polymers eudragit RSPO and RLPO. Int. J. Med. Pharm. Res.,  2018, 6(2), 50-61.

[26]
Department of Health and Aging, Australian Government of Therapeutic Goods Administration Australia. Australian public assessment report for Vildagliptin/Metformin hydrochloride. Ther. Goods Adm. About,  2010, 2020, 2-72.

[27]
Ferrannini, E.; Fonseca, V.; Zinman, B.; Matthews, D.; Ahrén, B.; Byiers, S.; Shao, Q.; Dejager, S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab.,  2009, 11(2), 157-166.
 [http://dx.doi.org/10.1111/j.1463-1326.2008.00994.x] [PMID: 19125777]

[28]
Mathieu, C.; Kozlovski, P.; Paldánius, P.M.; Foley, J.E.; Modgill, V.; Evans, M.; Serban, C. Clinical safety and tolerability of Vildagliptin - insights from randomised trials, observational studies and post-marketing surveillance. Eur. Endocrinol.,  2017, 13(2), 68-72.
 [http://dx.doi.org/10.17925/EE.2017.13.02.68] [PMID: 29632610]

[29]
Genees Middelen Informative Bank. Public Assessment Report. Vildagliptine Intas 50 Mg tablets. Coll. Ter Beoordeling Van Geneesmiddelen., 2020. Available from: https://www.geneesmiddeleninformatiebank.nl/pars/h124950.pdf

[30]
Shrikrishna, B.; Mulgund, S.V.; Ranpise, N.S. Simultaneous spectrophotometric estimation of Vildagliptin and Metformin in bulk and tablet dosage form. Der Pharm. Chem.,  2013, 5(1), 24-27.

[31]
Tammisetty, M.R.; Challa, B.R.; Puttagunta, S.B. A novel analytical method for the simultaneous estimation of remogliflozin and metformin hydrochloride by UPLC/PDA in bulk and formulation application to the estimation of product traces. Turkish J. Pharm. Sci.,  2021, 18(3), 296-305.
 [http://dx.doi.org/10.4274/tjps.galenos.2020.39699] [PMID: 34157819]

[32]
Ahrén, B.; Landin-Olsson, M.; Jansson, P.A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab.,  2004, 89(5), 2078-2084.
 [http://dx.doi.org/10.1210/jc.2003-031907] [PMID: 15126524]

[33]
Croxtall, J.D.; Keam, S.J. Vildagliptin a review of its use in the management of type 2 diabetes mellitus. Adis Drug Eval.,  2008, 68(16), 2387-2409.

[34]
Sakthimanigandan, K.; Ganesh, M.; Kanthikiran, V.; Sivakumar, T.; Jang, H. Liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the determination of Vildagliptin in rat plasma. Acta Chromatogr.,  2015, 27(2), 295-307.
 [http://dx.doi.org/10.1556/AChrom.27.2015.2.7]

[35]
Aher, V.; Mankar, S.D.; Shinde, G.S. Review on analytical methods for estimation of vildagliptin in bulk and pharmaceutical dosage form. Res. J. Sci. Technol.,  2021, 13(02), 157-162.
 [http://dx.doi.org/10.52711/2349-2988.2021.00024]

[36]
Olusola, A.M.; Adekoya, A.I.; Olanrewaju, O.J. Comparative evaluation of physicochemical properties of some commercially available brands of metformin Hcl tablets in Lagos, Nigeria. J. Appl. Pharm. Sci.,  2012, 2(2), 41-44.

[37]
Mansour, O.; Ismail, G.; Mostafaisbera, M.; Almouhammad, M. Assessment of physicochemical properties of Furosemide (40mg) tablets marketed in Syria. J. Chem. Pharm. Sci.,  2016, 9(4), 2879-2881.

[38]
Dailymed.. Glumetza TM 500mg (Metformin Hydrochloride extended release tablets) tablet, film coated, extended release. Food Drug Adm.,  2006, 21-748(002), 3-18.

[39]
Sambol, N.C.; Chiang, J.; O’Conner, M.; Liu, C.Y.; Lin, E.T.; Goodman, A.M.; Benet, L.Z.; Karam, J.H. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J. Clin. Pharmacol.,  1996, 36(11), 1012-1021.
 [http://dx.doi.org/10.1177/009127009603601105] [PMID: 8973990]

[40]
Al Bratty, M.; Alhazmi, H.A.; Alam, M.S.; Alam, M.I.; Javed, S.A.; Alam, N. Assessment of physicochemical properties and comparison of dissolution profiles of metformin hydrochloride tablets in Saudi Arabia. Dissolut. Technol.,  2020, 27(1), 36-44.
 [http://dx.doi.org/10.14227/DT270120P36]

[41]
Nanjwade, B.K.; Mhase, S.R.; Manvi, F.V. Formulation of extended-release metformin hydrochloride matrix tablets. Trop. J. Pharm. Res.,  2011, 10(4), 375-383.
 [http://dx.doi.org/10.4314/tjpr.v10i4.2]

[42]
Bian, X.; Jiang, L.; Gan, Z.; Guan, X.; Zhang, L.; Cai, L.; Hu, X. A glimepiride-metformin multidrug crystal: Synthesis, crystal structure analysis, and physicochemical properties. Molecules,  2019, 24(20), 3786.
 [http://dx.doi.org/10.3390/molecules24203786] [PMID: 31640214]

[43]
Kim, A.; Chung, I.; Yoon, S.H.; Yu, K.S.; Lim, K.S.; Cho, J.Y.; Lee, H.; Jang, I.J.; Chung, J.Y. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab. Dispos.,  2014, 42(7), 1174-1179.
 [http://dx.doi.org/10.1124/dmd.113.055616] [PMID: 24764147]

[44]
Scheen, A.J. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet.,  1996, 30(5), 359-371.
 [http://dx.doi.org/10.2165/00003088-199630050-00003] [PMID: 8743335]

[45]
Graham, G.G.; Punt, J.; Arora, M.; Day, R.O.; Doogue, M.P.; Duong, J.K.; Furlong, T.J.; Greenfield, J.R.; Greenup, L.C.; Kirkpatrick, C.M.; Ray, J.E.; Timmins, P.; Williams, K.M. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet.,  2011, 50(2), 81-98.
 [http://dx.doi.org/10.2165/11534750-000000000-00000] [PMID: 21241070]

[46]
Markowicz-Piasecka, M.; Huttunen, K.M.; Mateusiak, L.; Mikiciuk-Olasik, E.; Sikora, J. Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics. Curr. Pharm. Des.,  2017, 23(17), 2532-2550.
 [http://dx.doi.org/10.2174/1381612822666161201152941] [PMID: 27908266]

[47]
Gong, L.; Goswami, S.; Giacomini, K.M.; Altman, R.B.; Klein, T.E. Metformin pathways. Pharmacogenet. Genomics,  2012, 22(11), 820-827.
 [http://dx.doi.org/10.1097/FPC.0b013e3283559b22] [PMID: 22722338]

[48]
Mikhail, N. Remogliflozin etabonate: A novel SGLT2 inhibitor for treatment of diabetes mellitus. Expert Opin. Investig. Drugs,  2015, 24(10), 1381-1387.
 [http://dx.doi.org/10.1517/13543784.2015.1061501] [PMID: 26271274]

[49]
Napolitano, A.; Miller, S.; Murgatroyd, P.R.; Hussey, E.; Dobbins, R.L.; Bullmore, E.T.; Nunez, D.J.R. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J. Clin. Transl. Endocrinol.,  2014, 1(1), e3-e8.
 [http://dx.doi.org/10.1016/j.jcte.2013.12.001] [PMID: 29235586]

[50]
Shimizu, K.; Fujikura, H.; Fushimi, N.; Nishimura, T.; Tatani, K.; Katsuno, K.; Fujimori, Y.; Watanabe, S.; Hiratochi, M.; Nakabayashi, T.; Kamada, N.; Arakawa, K.; Hikawa, H.; Azumaya, I.; Isaji, M. Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor. Bioorg. Med. Chem.,  2021, 34, 116033.
 [http://dx.doi.org/10.1016/j.bmc.2021.116033] [PMID: 33581390]

[51]
Hussey, E.K.; Kapur, A.; O’Connor-Semmes, R.; Tao, W.; Rafferty, B.; Polli, J.W.; James, C.D., Jr; Dobbins, R.L. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol. Toxicol.,  2013, 14(1), 25.
 [http://dx.doi.org/10.1186/2050-6511-14-25] [PMID: 23631443]

[52]
Kleppinger, E.L.; Helms, K. The role of vildagliptin in the management of type 2 diabetes mellitus. Ann. Pharmacother.,  2007, 41(5), 824-832.
 [http://dx.doi.org/10.1345/aph.1H460] [PMID: 17456545]

[53]
Prasad, P.; Divya, K.; Ramana, M.; Krishnaveni, A.; Vinay, J.; Mahadeswar, M. Analytical method development and validation for the estimation of Vildagliptin in bulk and its dosage form using Uv spectrophotometer. Indo Am. J. Pharm. Res.,  2017, 7(12), 2231-6876.

[54]
Rena, G.; Hardie, D.G.; Pearson, E.R. The mechanisms of action of metformin. Diabetologia,  2017, 60(9), 1577-1585.
 [http://dx.doi.org/10.1007/s00125-017-4342-z] [PMID: 28776086]

[55]
Shah, J.; Kotadiya, R. Critical reviews in analytical chemistry A critical review on analytical methods for recently approved FDC drugs: Pregabalin and Etoricoxib A critical review on analytical methods for recently approved FDC drugs. Crit. Rev. Anal. Chem.,  2020, 2020, 1855411.
 [http://dx.doi.org/10.1080/10408347.2020.1855411] [PMID: 33307732]

[56]
Vidhi, D.; Patel, P. Method development and Validation of UV Spectrophotometric estimation of Remogliflozin Etabonate in bulk and its tablet dosage form. Res. J. Pharm. Technol.,  2021, 14(4), 2042-2044.
 [http://dx.doi.org/10.52711/0974-360X.2021.00362]

[57]
Kumari, B.; Khansili, A. Analytical method development and validation of UV-visible spectrophotometric method for the estimation of vildagliptin in gastric medium. Drug Res. (Stuttg.),  2020, 70(9), 417-423.
 [http://dx.doi.org/10.1055/a-1217-0296] [PMID: 32746479]

[58]
Naveed, S.; Rehman, H.; Qamar, F.; Zainab, S. Method development and validation of vildagliptin using UV spectrophotometer. Int. J. Pharm. Sci. Res.,  2014, 5(10), 714-717.

[59]
Moneeb, M.S. Spectrophotometric and spectrofluorimetric methods for the determination of saxagliptin and vildagliptin in bulk and pharmaceutical preparations. Bull. Fac. Pharm. Cairo Univ.,  2013, 51(2), 139-150.
 [http://dx.doi.org/10.1016/j.bfopcu.2013.03.003]

[60]
Housheh, S.; Mohammad, H.; Alahmad, Y. Spectrophotometric method for the determination of Vildagliptin in bulk and pharmaceutical dosage forms. Int. J. Pharm. Sci. Rev. Res.,  2019, 58(2), 117-120.

[61]
Banik, S.; Karmakar, P.; Miah, M.A.H. Development and validation of a UV-spectrophotometric method for determination of vildagliptin and linagliptin in bulk and pharmaceutical dosage forms. Bangladesh Pharm. J.,  2015, 18(2), 163-168.
 [http://dx.doi.org/10.3329/bpj.v18i2.24316]

[62]
Gundala, U.; Bhuvanagiri, C.S.; Nayakanti, D. Simultaneous estimation of vildagliptin and metformin in bulk and pharmaceutical formulations by UV spectrophotometry. Am. J. Pharmtech Res.,  2013, 3(1), 338-345.

[63]
El-Bagary, R.I.; Elkady, E.F.; Ayoub, B.M. Liquid chromatographic methods for the determination of vildagliptin in the presence of its synthetic intermediate and the simultaneous determination of pioglitazone hydrochloride and metformin hydrochloride. Int. J. Biomed. Sci.,  2011, 7(3), 201-208.
 [PMID: 23675237]

[64]
Raveendra, K.S.; Gaffar, S.M.; N., V.K. First derivative spectrophotometric simultaneous determination of Vildagliptin and metformin in tablet formulations. Pharmacophore,  2016, 7(2), 109-117.

[65]
Umapathi, P.; Ayyappan, J.; Quine, S.D. Quantitative determination of Metformin Hydrochloride in tablet formulation containing croscarmellose sodium as disintegrant by HPLC and UV spectrophotometry. Trop. J. Pharm. Res.,  2012, 11(1), 107-116.
 [http://dx.doi.org/10.4314/tjpr.v11i1.14]

[66]
Karim, R.; Poly, N.; Banoo, R. Development and validation of UV spectroscopic method for the determination of metformin. Int. J. Pharm. Sci. Res.,  2012, 3(09), 3170-3174.

[67]
Hassan, S.S.M.; Mahmoud, W.H.; Elmosallamy, M.A.F.; Othman, A.H.M. Determination of metformin in pharmaceutical preparations using potentiometry, spectrofluorimetry and UV-visible spectrophotometry. Anal. Chim. Acta,  1999, 378(1-3), 299-311.
 [http://dx.doi.org/10.1016/S0003-2670(98)00500-5]

[68]
Patil, V.P.; Angadi, S.S.; Kale, S.H.; Shelke, S.D.; Kawade, S.T.; Kadam, R.L. Stability indicating UV spectroscopic method for the estimation of metformin hydrochloride in bulk and tablets. Int. J. Pharm. Sci. Res.,  2015, 1(1), 27.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.IJLSR.1(1).27-33]

[69]
Dange, Y.D.; Honmane, S.M.; Bhinge, S.D.; Salunkhe, V.R.; Jadge, D.R. Development and validation of UV-spectrophotometric method for estimation of metformin in bulk and tablet dosage form. Indian J. Pharm. Edu. Res.,  2017, 51(4s), s754-s760.
 [http://dx.doi.org/10.5530/ijper.51.4s.109]

[70]
Shukla, R.; Singh, S.; Patel, J. Zero order and first order derivative spectrophotometric determination of Metformin HCL in bulk dosage form. Asian J. Pharm. Pharmacol.,  2016, 2(1), 6-9.

[71]
Judeh, A.A.; Sarief, A.; Umar, Y.; Ashwaq, O.; Haque, S.M. Development, computational studies and validation of spectrophotometric method of metformin hydrochloride in pharmaceutical formulations. J. Chil. Chem. Soc.,  2020, 65(3), 4895-4899.
 [http://dx.doi.org/10.4067/s0717-97072020000204895]

[72]
Önal, A. Spectrophotometric and HPLC determinations of anti-diabetic drugs, rosiglitazone maleate and metformin hydrochloride, in pure form and in pharmaceutical preparations. Eur. J. Med. Chem.,  2009, 44(12), 4998-5005.
 [http://dx.doi.org/10.1016/j.ejmech.2009.09.003] [PMID: 19781822]

[73]
Mali, A.D.; Mali, S.; Tamboli, A.; Bathe, R.; Simultaneous, U.V. spectrophotometric methods for estimation of metformin HCl and glimepiride in bulk and tablet dosage form. Int. J. Adv. Pharm.,  2015, 4(6), 117-123.
 [http://dx.doi.org/10.7439/ijap]

[74]
Chavhan, B.; Patil, P.; Bavaskar, S.; Barhate, S. Development and Validation of Analytical Method for Simultaneous Estimation of Glibenclamide and Metformin Hcl in Bulk and Tablets Using Uv-Visible. World J. Pharm. Res.,  2015, 4(11), 1257-1266.

[75]
Bhavyasri, K.; Surekha, T.; Sumakanth, M. A novel method development and validation of dapagliflozin and metormin hydrochloride using simultaneous equation method by UV- visible spectroscopy in bulk and combined pharmaceutical formulation including forced degradation studies. J. Pharm. Sci. Res.,  2020, 12(8), 1100-1105.

[76]
Zhang, G.Q.; Li, Y.S.; Zhao, Y.; Luo, Y.X.; Gao, X.F. A rapid and automated flow injection spectrophotometric determination method for pioglitazone/metformin hydrochloride in pharmaceutical preparation and to confirmation of its reaction principle using PCX column. Microchem. J.,  2020, 155, 104698.
 [http://dx.doi.org/10.1016/j.microc.2020.104698]

[77]
Mahgoub, H.; Youssef, R.M.; Korany, M.A.; Khamis, E.F.; Kamal, M.F. Development and validation of spectrophotometric and HPTLC methods for simultaneous determination of rosiglitazone maleate and metformin hydrochloride in the presence of interfering matrix excipients. Drug Dev. Ind. Pharm.,  2014, 40(9), 1190-1198.
 [http://dx.doi.org/10.3109/03639045.2013.810634] [PMID: 23829222]

[78]
Sujana, K.; Abbulu, K.; Bala Souri, O.; Archana, B.; Sindu, M.; Swathi Rani, G. Difference spectrophotometric methods for pioglitazone hydrochloride and metform in hydrochloride. J. Pharm. Sci. Res.,  2011, 3(4), 1122-1126.

[79]
Dadhania, K.; Nadpara, P.; Agrawal, Y. Development and validation of spectrophotometric method for simultaneous estimation of gliclazide and metformin hydrochloride in bulk and tablet dosage form by simultaneous equation method. Int. J. Pharm. Sci. Res.,  2011, 2(6), 1559-1563.

[80]
Riad, S.M.; Rezk, M.R.; Mahmoud, G.Y.; El Bayoumi, A.; Aleem, A. Spectrophotometric determination of sitagliptin and metformin in their pharmaceutical formulation. Int. J. Compr. Pharm.,  2012, 5(01), 1-4.

[81]
Hegazy, M.A.; El-Ghobashy, M.R.; Yehia, A.M.; Mostafa, A.A. Simultaneous determination of metformin hydrochloride and pioglitazone hydrochloride in binary mixture and in their ternary mixture with pioglitazone acid degradate using spectrophotometric and chemometric methods. Drug Test. Anal.,  2009, 1(7), 339-349.
 [http://dx.doi.org/10.1002/dta.60] [PMID: 20355212]

[82]
Sohrabi, M.R.; Kamali, N.; Khakpour, M. Simultaneous spectrophotometric determination of metformin hydrochloride and glibenclamide in binary mixtures using combined discrete and continuous wavelet transforms. Anal. Sci.,  2011, 27(10), 1037-1041.
 [http://dx.doi.org/10.2116/analsci.27.1037] [PMID: 21985929]

[83]
Fouad, M.; Rashed, N. Development and validation of chromatographic and spectroscopic methods for estimation of Repaglinide and Metformin HCl in combined dosage form. J. Glob. Trends Pharm. Sci.,  2014, 5(3), 1844-1848.

[84]
Joshi, R.S.; Nangare, A.K.; Sanap, D.S.; Sase, S.M. Development and validation of UV-Spectrophotometric Method for Estimation of Metformin Hydrochloride and Pioglitazone in Tablet Dosage Form. J. Drug Deliv. Ther.,  2019, 9(4-A), 381-384.
 [http://dx.doi.org/10.22270/jddt.v9i4-A.3499]

[85]
Nyola Narendra, G.J. Simultaneous estimation of saxagliptin hydrochloride and metformin hydrochloride in active pharmaceutical ingredient by RP-HPLC. Asian J. Pharm. Res. Heal. Care,  2017, 4(3), 70-77.
 [http://dx.doi.org/10.23959/sfdorj-1000025]

[86]
Chaturvedi, P.C.; Sharma, R. Development and validation of an RP-HPLC method for simultaneous analysis of a three-component tablet formulation containing metformin hydrochloride, pioglitazone hydrochloride, and glibenclamide. Acta Chromatogr.,  2008, 20(3), 451-461.
 [http://dx.doi.org/10.1556/AChrom.20.2008.3.11]

[87]
Cholke, P.; Shirsath, M.; Temak, Y.; Kagde, A.; Lagad, R. Development and Validation of UV-Visible Spectroscopy Method for Simultaneous Estimation of Saxagliptin Hydrochloride and Metformin Hydrochloride in Tablet Dosage Form. Int. J. Res. Pharm. Pharm. Sci.,  2018, 3(4), 31-34.

[88]
El-Bagary, R.I.; Elkady, E.F.; Ayoub, B.M. Spectrophotometric methods for the determination of linagliptin in binary mixture with metformin hydrochloride and simultaneous determination of linagliptin and metformin hydrochloride using high performance liquid chromatography. Int. J. Biomed. Sci.,  2013, 9(1), 41-47.
 [PMID: 23675288]

[89]
Majithia, R.H.; Khodadiya, D.A.; Patel, V.B. Spectrophotometric method development and validation for simultaneous estimation of Anagliptin and Metformin HCl BY Q - Absorption ratio method in synthetic mixture. Heliyon,  2020, 6(5), e03855.
 [http://dx.doi.org/10.1016/j.heliyon.2020.e03855] [PMID: 32405546]

[90]
Ashour, S.; Kabbani, R. Direct spectrophotometric determination of metformin hydrochloride in pure form and in drug formulations. Anal. Lett.,  2003, 36(2), 361-370.
 [http://dx.doi.org/10.1081/AL-120017696]

[91]
Basak, S.C.; Rahman, J.; Ramalingam, M. Design and in vitro testing of a floatable gastroretentive tablet of metformin hydrochloride. Pharmazie,  2007, 62(2), 145-148.
 [http://dx.doi.org/10.1691/ph.2007.2.6108] [PMID: 17341036]

[92]
Konari, S.N.; Jacob, J.T.; Prakash, V. Stability Indicating UV spectrophotometric method for linagliptin and metformin in pharmaceutical dosage form. Pharm. Methods,  2017, 8(2), 121-126.
 [http://dx.doi.org/10.5530/phm.2017.8.19]

[93]
Shokouhi, S.; Sohrabi, M.R. Net analyte signal and radial basis function neural network for development spectrophotometry method for the simultaneous determination of metformin and sitagliptin in anti-diabetic commercial tablet. Optik (Stuttg.),  2021, 243, 167518.
 [http://dx.doi.org/10.1016/j.ijleo.2021.167518]

[94]
Kharbade, S.; Asnani, A.; Pratyush, K. Development and validation of UV Spectrophotometric Method for simultaneous estimation of Metformin HCl and Repaglinide in pharmaceutical formulation. J. Drug Deliv. Ther.,  2019, 9(3), 344-347.

[95]
Jayasundara, U.K. Method development, validation, and concentration determination of metformin hydrochloride and atorvastatin calcium using UV-Visible Spectrophotometry. J. Anal. Bioanal. Tech.,  2021, 12(428), 2.

[96]
Prasanth, V.; Eapen, S. Development and validation of UV Spectroscopic Methods for the Estimation of Repaglinide and metformin hydrochloride in synthetic mixture. Int. J. Pharm. Sci. Heal.,  2012, 1(1), 1-8.

[97]
Narasimha, D.; Prasada Rao, M.; Hussain, J.N.; Sumanoja, S.L.; Rajeswara, V. Method development and validation of forced degradation studies of metformin hydrochloride by using UV spectroscopy. Int. J. Pharm. Chem. Biol. Sci.,  2013, 3(3), 546-553.

[98]
Anuruddha Chabukswar, P.S. RP-HPLC and UV-spectrophotometric methods development and validation for simultaneous estimation of teneligliptin and metformin in fixed dose combination. Curr. Pharma Res.,  2019, 9(3), 3146-3154.

[99]
Srivastav, A.; Tiwari, P.; Maheshwari, S. Development and validation of simultaneous equation UV-spectrophotometric method for the estimation of metformin HCL and glimepiride in combined dosage form. Asian J. Res. Chem,  2013, 9, 1-8.

[100]
Raghad, Kabbani; Kabbani, R.; Labban, R. Analytical spectrometric study for determining dapagliflozin propanediol monohydrate individually or in presence of metformin hydrochloride in tablets formulation. J. Adv. Chem.,  2020, 17, 80-87.
 [http://dx.doi.org/10.24297/jac.v17i.8812]

[101]
Suruse, S.; Mundhe, D. Simultaneous estimation of metformin and glimipride by ultraviolet spectrophotometry using absorbance ratio method. J. Curr. Pharm. Res.,  2012, 2(4), 611-614.
 [http://dx.doi.org/10.33786/JCPR.2012.v02i04.001]

[102]
Mubeen, G.; Noor, K.; Vimala, M.N. Spectrophotometric method for estimation of metformin hydrochloride. Int. J. Chemtech Res.,  2010, 2(2), 100-102.

[103]
Shankar, M.B.; Modi, V.D.; Shah, D.A.; Bhatt, K.K.; Mehta, R.S.; Geetha, M.; Patel, B.J. Estimation of pioglitazone hydrochloride and metformin hydrochloride in tablets by derivative spectrophotometry and liquid chromatographic methods. J. AOAC Int.,  2005, 88(4), 1167-1172.
 [http://dx.doi.org/10.1093/jaoac/88.4.1167] [PMID: 16152937]

[104]
Vrushali, K.B.; Snehal, G.G.; M, D.S.; Salim, P.G. Estimation of metformin hydrochloride in bulk and formulation by UV-spectroscopic area under curve method. J. Drug Deliv. Ther.,  2019, 9(3), 163-167.

[105]
Mishra, K.; Soni, H.; Nayak, G.; Patel, S.S.; Singhai, A.K. Method Development and Validation of Metformin Hydrochloride in Tablet Dosage Form. E-J. Chem.,  2011, 8(3), 1309-1313.
 [http://dx.doi.org/10.1155/2011/768014]

[106]
Arayne, M.S.; Sultana, N.; Zuberi, M.H.; Siddiqui, F.A. Spectrophotometric quantitation of metformin in bulk drug and pharmaceutical formulations using multivariate technique. Indian J. Pharm. Sci.,  2009, 71(3), 331-335.
 [http://dx.doi.org/10.4103/0250-474X.56022] [PMID: 20490308]

[107]
Patil, K.; Deshmukh, T.; Patel, V. A Stability indicating HPTLC method development and validation for analysis of vildagliptin as bulk drug from Its pharmaceutical dosage form. Int. J. Pharm. Sci. Res.,  2020, 11(5), 2310-2316.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.11(5).2310-16]

[108]
Bendale, A.R.; Singh, R.P.; Vidyasagar, G. Development and validation stability indicating HPTLC method for determination of vildagliptin and metformin hydrochloride in the pharmaceutical dosage forms. Int. J. Appl. Pharm.,  2018, 10(1), 36-45.
 [http://dx.doi.org/10.22159/ijap.2018v10i1.20555]

[109]
El-Kimary, E.I.; Hamdy, D.A.; Mourad, S.S.; Barary, M.A. HPTLC Determination of three gliptins in binary mixtures with metformin. J. Chromatogr. Sci.,  2015, 54(1), bmv106.
 [http://dx.doi.org/10.1093/chromsci/bmv106] [PMID: 26223462]

[110]
Shirode, A.; Maduskar, P.; Deodhar, M.; Kadam, V. RP-HPLC and HPTLC Methods for simultaneous estimation of metformin hydrochloride and vildagliptin from bulk and marketed formulation: development and validation. Br. J. Pharm. Res.,  2014, 4(20), 2370-2386.
 [http://dx.doi.org/10.9734/BJPR/2014/12820]

[111]
Khurd, A.; Miniyar, P.; More, S.; Doshi, K.; Gawande, V.; Sutar, A.; Kashid, A.; Tathe, S.; Gaikwad, S. Analytical method development and validation of vildagliptin by using quality by design approach. Eur. J. Biomed. Pharm. Sci.,  2020, 7(3), 223-229.

[112]
Butle, S.R.; Deshpande, P. Validated Stability-Indicating HPTLC Method development for determination of vildagliptin as bulk drug and in tablet dosage form. Eur. J. Pharm. Med. Res.,  2015, 2(6), 234-237.

[113]
Abdelwahab, N.S.; Abdelrahman, M.M.; Boshra, J.M.; Taha, A.A. Different chromatographic methods for the determination of antidiabetic drugs in the presence of drug toxic impurity. J. Planar Chromatogr. Mod. TLC,  2019, 32(4), 309-316.
 [http://dx.doi.org/10.1556/1006.2019.32.4.5]

[114]
Madhusudhan, P.; Reddy, M.R.; Devanna, N. A RP-HPLC Method development and validation for simultaneous estimation of metformin HCl and rosiglitazone in bulk and tablet dosage form. Pharm. Lett.,  2015, 7(3), 180-187.

[115]
Pritam, J.; Girase, D.; Anjali, B.; Sanjay, S. Stability- indicating HPTLC densitometric method for determination of metformin hydrochloride in tablet formulation. J. Pharm. Biosci.,  2013, 1, 51-58.
 [http://dx.doi.org/10.33786/JCPR.2019.v09i03.016]

[116]
Malani, A.; Kothapalli, L.; Bhimanwar, R. Development and validation of stability indicating high performance thin layer chromatographic method for simultaneous estimation of metformin hydrochloride and teneligliptin hydrobromide in combined dosage form. Int. Res. J. Pharm.,  2018, 9(6), 147-153.
 [http://dx.doi.org/10.7897/2230-8407.096107]

[117]
Thomas, A.B.; Patil, S.D.; Nanda, R.K.; Kothapalli, L.P.; Bhosle, S.S.; Deshpande, A.D. Stability-indicating HPTLC method for simultaneous determination of nateglinide and metformin hydrochloride in pharmaceutical dosage form. Saudi Pharm. J.,  2011, 19(4), 221-231.
 [http://dx.doi.org/10.1016/j.jsps.2011.06.005] [PMID: 23960763]

[118]
Sondarva, C.; Shah, K. Development and Validation of HPTLC method for simultaneous estimation of anti-diabetic drugs from their combined dosage form. J. Chil. Chem. Soc.,  2018, 11(2), 192-211.
 [http://dx.doi.org/10.4067/S0717-97072016000200021]

[119]
Modi, D.K.; Patel, B.H. Simultaneous determination of metformin hydrochloride and glipizide in tablet formulation by HPTLC. J. Liq. Chromatogr. Relat. Technol.,  2012, 35(1), 28-39.
 [http://dx.doi.org/10.1080/10826076.2011.593227]

[120]
B. Ahir, K.; Patelia, E.; Shah, A. Simultaneous estimation of metformin hydrochloride and repaglinide in pharmaceutical formulation by HPTLC-densitometry method. J. Chromatogr. Sep. Tech.,  2012, 4(1), 1-5.
 [http://dx.doi.org/10.4172/2157-7064.1000166]

[121]
Varade, R.; Mishra, H. A Rapid validated uni-dimensional double development Hptlc-densitometry method for simultaneous estimation of metformin hydrochloride, gliclazide and pioglitazone hydrochloride. Int. J. Pharm. Pharm. Sci.,  2019, 11(7), 74-80.
 [http://dx.doi.org/10.22159/ijpps.2019v11i7.31586]

[122]
Patel, K.K.; Karkhanis, V.V.; Gajjar, S.S. Development and validation of stability indicating HPTLC method for estimation of glimepiride and metformin hydrochloride. Int. J. Pharm. Sci. Res.,  2015, 6(3), 1222-1229.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.6(3).1222-29]

[123]
Sharma, K.; Parle, A.; Ahmad, S. Development and validation of HPTLC method for simultaneous estimation of metformin hydrochloride and alogliptin benzoate in bulk drugs and combined dosage forms. Sch. Res. Libr.,  2015, 7(7), 321-328.

[124]
Magdy, M.A.; Ali, N.W.; Taha, A.A.; Elgebaly, A.M.; Farid, N.F. Different chromatographic methods for determination of alogliptin benzoate, metformin hydrochloride, and metformin impurity in bulk and pharmaceutical dosage form. J. Sep. Sci.,  2021, 44(4), 833-842.
 [http://dx.doi.org/10.1002/jssc.202000937] [PMID: 33301650]

[125]
Manjushak, N.; Solomon, W.D.S.; Venkatanarayanan, R. Research article HPTLC method for simultaneous estimation of metformin HCl and sitagliptin in pharmaceutical dosage form. J. Innov. Pharm. Biol. Sci.,  2016, 3(3), 69-74.

[126]
Munde, M.K.; Kulkarni, N.S.; Sen, A.K.; Sen, D.B. A Novel validated stability indicating analytical method for simultaneous quantification of metformin hydrochloride and empagliflozin in bulk and marketed formulation by HPTLC using box-wilson experimental design approach. Indian J. Pharm. Edu. Res.,  2020, 54(3s), s644-s656.
 [http://dx.doi.org/10.5530/ijper.54.3s.164]

[127]
Patel, M.; Patel, D.; Shah, U.; Kachhiya, H.M. Simultaneous quantification of teneligliptin hydrobromide and metformin hydrochloride: An improved HPTLC method with implementation of Plackett-Burman design. J. Chem. Metrol.,  2021, 15(1), 65-75.
 [http://dx.doi.org/10.25135/jcm.55.20.11.1893]

[128]
Rank, M.; Kapupara, P.; Shah, K. Development and validation of stability indicating HPTLC method for pioglitazone hydrochloride and metformin hydrochloride. Res. J. Pharm. Technol.,  2016, 9(10), 1555.
 [http://dx.doi.org/10.5958/0974-360X.2016.00305.X]

[129]
Malgundkar, S.; Mulla, S. Validated Hptlc method for simultaneous determination of ceftriaxone sodium and tazobactam sodium in combined dosage form. IOSR J. Pharm. Biol. Sci.,  2014, 9(2), 60-65.
 [http://dx.doi.org/10.9790/3008-09256065]

[130]
Abdelhamid, N.S.; Elsaady, M.T.; Ali, N.W.; Abuelazem, W.G. simultaneous determination of repaglinide, metformin hydrochloride and melamine by new HPLC and HPTLC chromatographic methods. Anal. Chem. Lett.,  2019, 9(3), 418-429.
 [http://dx.doi.org/10.1080/22297928.2019.1622450]

[131]
Jitendra, P.P.; Hinge, M. Simultaneous estimation of metformin hydrochloride and alpha lipoic acid by HPTLC method in tablet dosage form. Adv. Pharmacoepidemiol. Drug Saf.,  2020, 9, 236.
 [http://dx.doi.org/10.35248/2167-1052.20.9.236.Copyright]

[132]
Sakhare, R.S.; Pekamwar, S.S.; Mohkare, D.P. Development and validation of stability indicating HPTLC method for the determination of metformin hydrochloride and benfotiamine in bulk and combined dosage form. Indian J. Pharm. Edu. Res.,  2017, 51(2s), s8-s16.
 [http://dx.doi.org/10.5530/ijper.51.2s.44]

[133]
Bhole, R.P.; Gandhi, J.S.; Wankhede, S.B. Development and validation of HPTLC method for simultaneous estimation of canagliflozin and metformin hydrochloride in bulk and tablet dosage form. S. Afr. Pharm. J.,  2017, 84(6), 65-71.

[134]
Sanjay, G.; Walode, A.V.K. Quantitative planner chromatographic method development for sitagliptin phosphate monohydrate and metformin hydrochloride in presence of their degradation product. Asian J. Res. Chem,  2015, 7, 1-26.

[135]
Jadhav, S.; Kupkar, S.; Dharam, D.; Jangam, A.; Chaudhari, P. Development and validation of RP-HPLC and HPTLC methods for simultaneous estimation of sitagliptin phosphate and metformin hydrochloride in bulk and dosage form. Indian J. Pharm. Educ. Res.,  2012, 47(1), 13-16.

[136]
Havele, S.S.; Dhaneshwar, S.R. Simultaneous determination of metformin hydrochloride in its multicomponent dosage forms with sulfonyl ureas like gliclazide and glimepiride using HPTLC. J. Liq. Chromatogr. Relat. Technol.,  2011, 34(12), 966-980.
 [http://dx.doi.org/10.1080/10826076.2011.557465]

[137]
Barge, V.; Warghade, S.; Devlekar, N.N.; Patil, R.Y. Validated HPTLC method for simultaneous estimation of sitagliptin and metformin hydrochloride in bulk drug and formulation. Res. Rev. J. Pharm. Anal.,  2014, 3(3), 45-50.

[138]
Dhaneshwar, S.R.; Salunkhe, J.V.; Bhusari, V.K. Validated HPTLC Method for Simultaneous Estimation of Metformin Hydrochloride, Atorvastatin and Glimepiride in Bulk Drug and Formulation. J. Anal. Bioanal. Tech.,  2010, 1(3), 1-5.
 [http://dx.doi.org/10.4172/2155-9872.1000109]

[139]
Susheel, J.; Paul, D.; Ravi, T. Development and validation of highperformance thin- layer chromatography method for the simultaneous densitometric determination of metformin and rosiglitazone in tablets. Austin J. Anal. Pharm. Chem.,  2016, 3(3), 1071/1-1071/4.

[140]
Raja, T.; Lakshmana Rao, A. Validated HPTLC method for simultaneous estimation of metformin hydrochloride and sitagleptin phosphate in bulk drug and formulation. Rasayan J. Chem.,  2012, 5(3), 407-413.

[141]
Patil, V.; Kale, S.; Sahare, P.; Vithaldas, S. Simultaneous HPTLC analysis of gliclazide and metformin hydrochloride in bulk and tablet dosage form. J. Sci. Innovat. Res.,  2014, 3(3), 325-331.
 [http://dx.doi.org/10.31254/jsir.2014.3309]

[142]
Reddy, B.K.K.; Sekhar, K.B.C.; Mohan, C.K. Bioanalytical method development and validation for the simultaneous determination of vildagliptin and telmisartan in rabbit plasma using RP-HPLC. J. Pharm. Res. Int.,  2021, 33(1), 76-86.
 [http://dx.doi.org/10.9734/jpri/2021/v33i131141]

[143]
Boovizhikannan, T.; Palanirajan, V.K. RP-HPLC determination of vildagliptin in pure and in tablet formulation. J. Pharm. Res.,  2013, 7(1), 113-116.
 [http://dx.doi.org/10.1016/j.jopr.2013.01.001]

[144]
Shakoor, A.; Ahmed, M.; Ikram, R.; Hussain, S.; Tahir, A.; Jan, B.M.; Adnan, A. Stability-indicating RP-HPLC method for simultaneous determination of metformin hydrochloride and vildagliptin in tablet and biological samples. Acta Chromatogr.,  2020, 32(1), 39-43.
 [http://dx.doi.org/10.1556/1326.2019.00555]

[145]
Chaphekar, M.; Hamrapurkar, P. Development and validation of RP-HPLC assay method for vildagliptin using Qbd approach. Indian J. Res. Pharm. Biotechnol.,  2016, 8(03), 157-165.

[146]
Malakar, A.; Bokshi, B.; Nasrin, D. Development and validation of RP - HPLC method for estimation of vildagliptin from tablet dosage form. Int. J. Pharm. Life Sci. Vol.,  2012, 1(1), 37-39.

[147]
Manohar, K.; Thangabalan, B.; Babu, S.M. Method development and validation for the simultaneous estimation of vildagliptin and metformin in tablet dosage form by RP - HPLC. Int. J. Res. Pharm. Nano Sci.,  2014, 3(2), 80-87.

[148]
Attimarad, M.; Nagaraja, S.H.; Aldhubaib, B.E.; Al-Najjar, A. Development of a rapid reversed phase-high performance liquid chromatography method for simultaneous determination of metformin and vildagliptin in formulation and human plasma. J. Young Pharm.,  2014, 6(4), 40-46.
 [http://dx.doi.org/10.5530/jyp.2014.4.7]

[149]
Amin, M.M.; Abdel-Aziz, S.A.; Mostafa, S.M.; El-Adl, S.M. Optimization and validation of HPLC method for simultaneous determination of vildagliptin, pioglitazone hydrochloride and glimepiride in bulk and tablets. IOSR J. Pharm. Biol. Sci.,  2017, 12(2), 18-27.
 [http://dx.doi.org/10.9790/3008-1202041827]

[150]
Satheeshkumar, N.; Pradeepkumar, M.; Shanthikumar, S.; Rao, V. Development of validated stability indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC. Drug Res. (Stuttg.),  2013, 64(3), 124-129.
 [http://dx.doi.org/10.1055/s-0033-1354373] [PMID: 24081820]

[151]
Shaikh, N.K.; Jat, R.; Bhangale, J.O. Analysis Of vildagliptin And nateglinide For simultaneous estimation using spectro-chromatographic methods. Eur. J. Mol. Clin. Med.,  2020, 07(08), 741-755.

[152]
Jayaprakash, R.; Natesan, S.K. Stability Indicating RP - HPLC Method development and validation for the simultaneous determination of vildagliptin and metformin in pharmaceutical dosage form. Int. J. Pharm. Pharm. Sci.,  2017, 9(3), 150-157.
 [http://dx.doi.org/10.22159/ijpps.2017v9i3.16233]

[153]
Sultana, R.; Bachar, S.; Rahman, F. Development and validation of stability indicating assay method of vildagliptin in bulk and tablet dosage form by RP-HPLC article. Int. J. Pharm. Life Sci.,  2013, 4(4), 2530-2534.

[154]
Savale, S.K. Development and validation of RP-HPLC method for estimation of vildagliptin. Asian J. Biomater. Res.,  2017, 3(5), 6-11.
 [http://dx.doi.org/10.1177/145507259801500307]

[155]
Napate, V.G.; Anantrao Napate, P. Method Development and Validation for the Vildagliptin by RP - HPLC Method. Asian J. Pharm. Anal. Med. Chem.,  2020, 8(1), 24-31.
 [http://dx.doi.org/10.36673/AJPAMC.2020.v08.i01.A04]

[156]
Dayyih, W.A.; Hamad, M.; Mallah, E.; Dayyih, A.A.; Awad, R.; Zakaria, Z.; Arafat, T. Method development And validation of vildagliptin and metformin HCL in pharmaceutical dosage form by reversed phase-high performance liquid chromatography (RP-HPLC). Int. J. Pharm. Sci. Res.,  2018, 9(7), 2965.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.9(7).2965-72]

[157]
Barden, A.T.; Salamon, B.; Schapoval, E.E.S.; Steppe, M. Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product. J. Chromatogr. Sci.,  2012, 50(5), 426-432.
 [http://dx.doi.org/10.1093/chromsci/bms024] [PMID: 22511486]

[158]
Martín, J.; Buchberger, W.; Santos, J.L.; Alonso, E.; Aparicio, I. High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2012, 895-896, 94-101.
 [http://dx.doi.org/10.1016/j.jchromb.2012.03.023] [PMID: 22483984]

[159]
Rao, K.H.; Rao, A.L.; Sekhar, K.B.C.; Pradesh, A.; Sciences, P.; Pradesh, A. Development and validation of HPLC method for the estimation of vildagliptin in pharmaceutical dosage form. Int. J. Pharm. Chem. Biol. Sci.,  2014, 4(2), 361-366.

[160]
Varma, D. A. L. R. and S. C. D. Simultaneous determination of metformin and vildagliptin in solid dosage form by stability indicating RP-HPLC method. Int. Res. J. Pharm.,  2013, 4(1), 19-27.

[161]
Khatun, R.; Mirazzunnabi, M. A Validated reversed-phase HPLC method for the determination of vildagliptin from tablet dosage form. Int. J. Pharm. Life Sci.,  2013, 2(3), 90-98.
 [http://dx.doi.org/10.3329/ijpls.v2i3.15455]

[162]
Rao, B.S.; Dubey, S.S.; Rao, K.N.; Kiran, B.V. Development and validation of a reverse phase HPLC method for the determination of metformin HCl in pharmaceutical dosage forms. Asian J. Chem.,  2012, 24(12), 5460-5462.

[163]
Chhetri, H.; Thapa, P.; Schepdael, A. HPLC Method for the quantification of metformin hydrochloride in bulk and dosage forms. Int. J. Pharm. Sci. Res.,  2013, 4(7), 2600-2604.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.4(7).2600-04]

[164]
Arayne, M.S.; Sultana, N.; Zuberi, M.H. Development and validation of RP-HPLC method for the analysis of metformin. Pak. J. Pharm. Sci.,  2006, 19(3), 231-235.
 [PMID: 16935831]

[165]
Kar, M.; Choudhury, P.K. HPLC method for estimation of metformin hydrochloride in formulated microspheres and tablet dosage form. Indian J. Pharm. Sci.,  2009, 71(3), 318-320.
 [http://dx.doi.org/10.4103/0250-474X.56031] [PMID: 20490303]

[166]
Nikam, M. N.; Maru, D. A.; Malpure, D. A. J. Analytical method development and validation of metformin hydrochloride by using RP-HPLC with ICH guidelines. Int. J. Trend Sci. Res. Dev.,  2019, 3(3), 415-419.
 [http://dx.doi.org/10.31142/ijtsrd22812]

[167]
Rajan, V.; Rele, S.P.P. Application of RP - HPLC technique for development of analytical method for validation of metformin hydrochloride from bulk and dosage form. Asian J. Res. Chem,  2021, 14(4), 1-17.

[168]
Patan, A.; Basha, S.R.; Ketha, R.K.; Cheriyan, B.V.; Muthukumar, V.A. Development and validation of new RP-HPLC method for the simultaneous estimation of metformin hydrochloride and repaglinide in pure and pharmaceutical formulations. Res. J. Pharm. Technol.,  2021, 14(3), 1323-1328.
 [http://dx.doi.org/10.5958/0974-360X.2021.00235.3]

[169]
Patel, A.M. Stability Indicating RP-HPLC RP - HPLC Method development and validation for estimation of empagliflozin and metformin HCl. World J. Pharm. Pharm. Sci.,  2017, 6(9), 872-885.
 [http://dx.doi.org/10.20959/wjpps20179-9806]

[170]
Musmade, B.D.; Baraskar, M.L.; Ghodke, V.N.; Bhope, S.G.; Padmanabhan, S.; Lohar, K.S. Impurity profiling method development and validation of metformin hydrochloride and teneligliptin hydrobromide hydrate in their combination tablet dosage form by using RP-HPLC with UV/PDA detector. Future J. Pharm. Sci.,  2021, 7(1), 218.
 [http://dx.doi.org/10.1186/s43094-021-00362-9]

[171]
Snehal, B.; Prerana, J. Development and validation of RP-HPLC method for simultaneous estimation of metformin hydrochloride and glipizide in bulk and pharmaceutical dosage form. J. Drug Deliv. Ther.,  2019, 9(3), 146-155.

[172]
Soni, L.K.; Narsinghani, T.; Jain, M. Development and validation of Rp-Hplc method for simultaneous estimation of metformin hydrochloride and repaglinide in tablet dosage form. J. Liq. Chromatogr. Relat. Technol.,  2012, 35(3), 385-392.
 [http://dx.doi.org/10.1080/10826076.2011.601492]

[173]
Nagaraju, P.; Devi, G.P. Method development and validation for simultaneous estimation of metformin HCl and myo-inositol in pharmaceutical dosage form by using RP - HPLC. World J. Adv. Healthc. Res.,  2021, 5(3), 389-402.

[174]
Al-Rimawi, F. Development and validation of an analytical method for metformin hydrochloride and its related compound (1-cyanoguanidine) in tablet formulations by HPLC-UV. Talanta,  2009, 79(5), 1368-1371.
 [http://dx.doi.org/10.1016/j.talanta.2009.06.004] [PMID: 19635372]

[175]
Gadapa, N.; Tripathi, U.M. RP-HPLC Analytical method development and validation for simultaneous estimation of two drugs nitazoxanide, ofloxacin and its pharmaceutical dosage forms. Int. J. Chemtech Res.,  2012, 4(2), 775-783.

[176]
Merey, H.A.; Ramadan, N.K.; Diab, S.S.; Moustafa, A.A. Chromatographic methods for the simultaneous determination of binary mixture of Saxagliptin HCl and Metformin HCl. Bull. Fac. Pharm. Cairo Univ.,  2017, 55(2), 311-317.
 [http://dx.doi.org/10.1016/j.bfopcu.2017.04.002]

[177]
Nyola, J. K.; Govindasamy, J. Sitagliptin and metformin hydrochloride in pure and tablet dosage form by UV-VIS spectroscopy. World J. Pharm. Pharm. Sci.,  2012, 1(4), 1392-1401.

[178]
Chhetri, H.P.; Thapa, P.; Van Schepdael, A. Simple HPLC-UV method for the quantification of metformin in human plasma with one step protein precipitation. Saudi Pharm. J.,  2014, 22(5), 483-487.
 [http://dx.doi.org/10.1016/j.jsps.2013.12.011] [PMID: 25473337]

[179]
Neelima, K.; Prasad, Y.R. Analytical method development and validation of metformin, voglibose, glimepiride in bulk and combined tablet dosage form by gradient RP-HPLC. Pharm. Methods,  2014, 5(1), 27-33.
 [http://dx.doi.org/10.5530/phm.2014.1.5]

[180]
Kumari, K.S.; Bandhakavi, S. Development and validation of stability-indicating RP-HPLC method for the simultaneous determination of ertugliflozin pidolate and metformin hydrochloride in bulk and tablets. Future J. Pharm. Sci.,  2020, 6(1), 66.
 [http://dx.doi.org/10.1186/s43094-020-00079-1]

[181]
Lakshmi, K.S.; Rajesh, T.; Sharma, S. Simultaneous determination of metformin and pioglitazone by reversed phase HPLC in pharmaceutical dosage forms. Int. J. Pharm. Pharm. Sci.,  2009, 1(2), 162-166.

[182]
Rana, K.; Sharma, P. Development and validation of a HPLC method for the determination of metformin hydrochloride, nateglinide and pioglitazone hydrochloride in multicomponent formulation. Asian J. Res. Chem,  2021, 14(1), 7-12.
 [http://dx.doi.org/10.5958/0974-4150.2021.00002.X]

[183]
Priya V. P, M.; Kumar, P.; Kumar, R. RP-HPLC Method for Simultaneous Estimation of Metformin HCL, Ramipril and Glimepiride in Bulk and Their Combination Tablet Dosage Form. J. Pharm. Biol. Sci.,  2016, 11(3), 16-23.
 [http://dx.doi.org/10.9790/3008-1103041623]

[184]
Mahrouse, M.A.; Lamie, N.T. Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate and repaglinide in tablets. Microchem. J.,  2019, 147, 691-706.
 [http://dx.doi.org/10.1016/j.microc.2019.03.038]

[185]
Tgk, M.; Geethanjali, J. Development of a Validated RP-HPLC Method for Simultaneous Estimation of Metformin Hydrochloride and Rosuvastatin Calcium in Bulk and In-House Formulation. J. Chromatogr. Sep. Tech.,  2014, 5(6), 5-11.
 [http://dx.doi.org/10.4172/2157-7064.1000252]

[186]
Sirigiri, N.; Subramanian, N.S.; Reddy, N.K. Stability Indicating Method Development and Validation for Simultaneous Estimation of Linagliptin and Metformin HCl in Tablets by HPLC. Int. J. Pharm. Sci. Res.,  2018, 9(10), 4294-4302.

[187]
Nirupama, D.; Venkateswara, P.; Thangabalan, B.; Manohar, B. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Gliclazide and Metformin in Pure and Tablet Dosage Form. Int. J. Pharm. Anal. Res.,  2014, 3(4), 326-333.

[188]
Chaturvedi, P.K.; Sharma, R. Simultaneous spectrophotometric estimation and validation of three component tablet formulation containing pioglitazone hydrochloride, metformin hydrochloride and glibenclamide. Anal. Lett.,  2008, 41(12), 2133-2142.
 [http://dx.doi.org/10.1080/00032710802240834]

[189]
Sharma, R.; Chaturvedi, S.C.; Sahoo, P.K. Simultaneous estimation of metformin hydrochloride and pioglitazone hydrochloride by RPHPLC method from combined tablet dosage form. Indian J. Pharm. Sci.,  2008, 70(3), 383-386.
 [http://dx.doi.org/10.4103/0250-474X.43010] [PMID: 20046754]

[190]
Bhamare, P.C.; Bari, S.B.; Natarajan, S.; Patil, A.A.; Patil, S.H.; Shirode, P.T. Development and validation of a precise single stability indicating HPLC method for determinations of metformin hydrochloride and fenofibrate, in pure form and in pharmaceutical tablets. Int. J. Pharm. Tech. Res.,  2011, 3(1), 505-515.

[191]
Chengalva, P.; Angala Parameswari, S.; Aruna, G. Development and validation of Rp-Hplc method for metformin hydrochloride and nateglinide in bulk and combined dosage form. Int. J. Pharm. Pharm. Sci.,  2016, 8(4), 267-271.

[192]
Vetapalem, R.; Yejella, R.; Atmakuri, L. Development and validation of stability indicating RP-HPLC method for simultaneous estimation of teneligliptin and metformin. Asian J. Pharm. Res. Heal. Care,  2008, 1, 1-10.

[193]
Peraman, R.; Gowra, C.S.; Reddy, Y.P.; Peruru, K.K. Stability-Indicating RP-HPLC method for simultaneous determination of metformin hydrochloride and sitagliptin phosphate in dosage forms. Chromatographia,  2013, 76(17-18), 1153-1162.
 [http://dx.doi.org/10.1007/s10337-013-2525-4]

[194]
Pandya, R.; Rathod, R.; Maheswari, D. Bioanalytical method development and validation for simultaneous determination of linagliptin and metformin drugs in human plasma by RP-HPLC Method. Pharmacophore,  2014, 5(2), 202.

[195]
Gurav, S.B.; Manish, N. Development and validation of novel stability- indicating LC method for the determination of saxagliptin and metformin. Indian J. Pharm. Edu. Res.,  2020, 54(2s), s350-s357.
 [http://dx.doi.org/10.5530/ijper.54.2s.93]

[196]
Aslan, S.S.; Yılmaz, B. Derivative spectrophotometric and isocratic high performance liquid chromatographic methods for simultaneous determination of repaglinide and metformin hydrochloride in pharmaceutical preparations. Am. J. Anal. Chem.,  2017, 8(9), 541-552.
 [http://dx.doi.org/10.4236/ajac.2017.89039]

[197]
D’souza, S.; Krishna, M.; Sushmitha, G.; Vasantharaju, S. Stability indicating assay method development and validation to simultaneously estimate metformin hydrochloride and canagliflozin by RP-HPLC. Res. J. Pharm. Technol.,  2016, 10(4), 334-342.
 [http://dx.doi.org/10.5958/0974-360X.2016.00225.0]

[198]
Hassib, S.T.; Taha, E.A.; Elkady, E.F.; Barakat, G.H. Validated liquid chromatographic method for the determination of (canagliflozin, dapagliflozin or empagliflozin) and metformin in the presence of (1-Cyanoguanidine). J. Chromatogr. Sci.,  2019, 57(8), 697-707.
 [http://dx.doi.org/10.1093/chromsci/bmz042] [PMID: 31240304]

[199]
Khoja, S.S.; Patel, L.J. Development and validation of new RP-HPLC method for the estimation of antidiabetic drugs metformin hydrochloride and gemigliptin in combined pharmaceutical dosage form. J. Pharm. Res. Int.,  2021, 10, 149-160.
 [http://dx.doi.org/10.9734/jpri/2021/v33i30B31649]

[200]
Akshay, N.; Chandan, R. Stability indicating assay method for the simultaneous estimation of Empagliflozin and Metformin HCl by RP-HPLC method. Int. J. Res. Pharm. Sci.,  2020, 11(3), 3933-3941.
 [http://dx.doi.org/10.26452/ijrps.v11i3.2583]

[201]
Maity, S.; Patra, S.K. Development of reverse phase HPLC method and validation for the estimation of metformin hydrochloride and glipizide in combined dosage form. J. Chem. Pharm. Res.,  2018, 10(3), 142-147.

[202]
Deepan, T.; Basaveswararao, M.; Dhanaraju, M. Development of validated stability indicating assay method for simultaneous estimation of metformin and dapagliflozin by RP- HPLC. Eur. J. Appl. Sci.,  2017, 9(4), 189-199.
 [http://dx.doi.org/10.1055/s-0033-1354373]

[203]
Panigrahy, U.; Reddy, A. A Novel validated RP-HPLC-DAD method for the simultaneous estimation of metformin hydrochloride and canagliflozin in bulk and pharmaceutical tablet dosage form with forced degradation studies. Orient. J. Chem.,  2015, 31(3), 1489-1507.
 [http://dx.doi.org/10.13005/ojc/310328]

[204]
Vankalapati, K.R.; Alegete, P.; Boodida, S. Stability‐indicating HPLC method development and validation for simultaneous estimation of metformin, dapagliflozin, and saxagliptin in bulk drug and pharmaceutical dosage form. Biomed. Chromatogr.,  2022, 36(7), e5384.
 [http://dx.doi.org/10.1002/bmc.5384] [PMID: 35434817]

[205]
Hickey, A.J.; Rao, S. dosage forms. Int. Res. J. Pharm. Med. Sci.,  2018, 1(5), 15-31.
 [http://dx.doi.org/10.1016/B978-0-12-812209-9.00002-6]

[206]
Panchal, W.; Wadekar, A.; Manwar, J.; Malode, G.; Chaudhari, K.; Bakal, R. RP-HPLC Method for simultaneous determination of ibuprofen and famotidine in pharmaceutical dosage form. World J. Pharm. Med. Res. Med. Res.,  2021, 7(5), 234-238.

[207]
Priyanka, K.; Prasanna, A. Method development and validation of simultaneous determination of metformin and saxagliptin in pharmaceutical dosage form by RP - HPLC. Int. J. Chemtech Res.,  2015, 5(1), 381-387.

[208]
Patel, V.A.; Pandya, C.V.; Patel, Z.J.; Patel, D.R.; Pandya, A.C. Development and validation of novel RP - UHPLC/DAD methods for simultaneous quantification of remogliflozin and metformin in bulk and formulation. Rasayan J. Chem.,  2021, 14(2), 1384-1393.
 [http://dx.doi.org/10.31788/RJC.2021.1426295]

[209]
Fouad, M.M. RP-UPLC Method development and validation for simultaneous estimation of vildagliptin with metformin hydrochloride and ciprofloxacin hydrochloride with dexamethasone sodium phosphate. World J. Pharm. Sci.,  2015, 3(9), 1755-1762.

[210]
Sultana, S.; Kumar, U.; Hossain, M.S.; Lira, D.N.; Rouf, A.S.S. QbD approach for the development and validation of RP-UHPLC method for quantitation of vildagliptin. Dhaka Univ. Pharmaceut. Sci.,  2017, 16(1), 107-117.
 [http://dx.doi.org/10.3329/dujps.v16i1.33388]

[211]
Ayoub, B.M. UPLC simultaneous determination of empagliflozin, linagliptin and metformin. RSC Advances,  2015, 5(116), 95703-95709.
 [http://dx.doi.org/10.1039/C5RA17231D]

[212]
Malleswararao, C.S.N.; Suryanarayana, M.V.; Mukkanti, K. Simultaneous determination of sitagliptin phosphate monohydrate and metformin hydrochloride in tablets by a validated UPLC method. Sci. Pharm.,  2012, 80(1), 139-152.
 [http://dx.doi.org/10.3797/scipharm.1110-13] [PMID: 22396910]

[213]
Bandarkar, F.S.; Khattab, I.S. Simultaneous estimation of glibenclamide, gliclazide, and metformin hydrochloride from bulk and commercial products using a validated ultra fast liquid chromatography technique. J. Liq. Chromatogr. Relat. Technol.,  2010, 33(20), 1814-1830.
 [http://dx.doi.org/10.1080/10826076.2010.532704]

[214]
Mowaka, S.; Ayoub, B.M. Comparative study between UHPLC-UV and UPLC-MS/MS methods for determination of alogliptin and metformin in their pharmaceutical combination. Pharmazie,  2017, 72(2), 67-72.
 [http://dx.doi.org/10.1691/ph.2017.6151] [PMID: 29441855]

[215]
Patel, V.; Pandya, C.; Patel, Z.; Patel, D.; Pandya, A. Isocratic RP-UHPLC method development and validation of stability-indicating for simultaneous determination of teneligliptin and metformin in fixed-dose combination. Curr. Chem. Lett.,  2021, 10(4), 503-516.
 [http://dx.doi.org/10.5267/j.ccl.2021.4.001]

[216]
Uçaktürk, E. Development of Sensitive and specific analysis of vildagliptin in pharmaceutical formulation by gas chromatography-mass spectrometry. J. Anal. Methods Chem.,  2015, 2015, 707414.
 [http://dx.doi.org/10.1155/2015/707414] [PMID: 26682085]

[217]
Pontarolo, R.; Gimenez, A.C.; de Francisco, T.M.G.; Ribeiro, R.P.; Pontes, F.L.D.; Gasparetto, J.C.; Pontes, D.; Gasparetto, J.C. Simultaneous determination of metformin and vildagliptin in human plasma by a HILIC-MS/MS method. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2014, 965, 133-141.
 [http://dx.doi.org/10.1016/j.jchromb.2014.06.023] [PMID: 25016166]

[218]
Tiwari, A.; Vandana, S.; Siddiqui, A.W.; Panigrahy, B.K. Arshad Khuroo; Lalit, T. Bioanalytical method development and validation of vildagliptin in rat plasma using LCMS/MS method. Int. J. Adv. Sci. Res.,  2019, 10(3), 22-29.

[219]
de Andrade, C.; de Araújo Lock, G.; Pigatto, M.C.; Haas, S.E.; Costa, T.D.; de Araújo, B.V. Validation of LC-MS/MS method applied to evaluation of free tissue concentrations of vildagliptin in diabetic rats by microdialysis. Biomed. Chromatogr.,  2014, 28(12), 1722-1727.
 [http://dx.doi.org/10.1002/bmc.3212] [PMID: 24771661]

[220]
Ferrazza, C.; Giordani, A.; Campanharo, S.; Wingert, N. R.; Bueno, L. M.; Manoel, J. W.; Garcia, C. V.; Volpato, N. M.; Iop, G. D.; Mello, P. D. A.; Marlon, E.; Flores, D. M.; Eva, E.; Schapoval, S.; Steppe, M. UPLC-ESI / Q-TOF MS / MS method for determination of Vildagliptin and its organic impurities. J. Chromatogr. Sci.,  2020, 2020, 1-8.
 [http://dx.doi.org/10.1093/chromsci/bmaa040]

[221]
Jagadeesh, B.; Bharathi, D.V.; Pankaj, C.; Narayana, V.S.; Venkateswarulu, V. Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2013, 930, 136-145.
 [http://dx.doi.org/10.1016/j.jchromb.2013.04.024] [PMID: 23732843]

[222]
Abbas Moussa, B.; Mahrouse, M.A.; Fawzy, M.G. A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. J. Pharm. Biomed. Anal.,  2019, 163, 153-161.
 [http://dx.doi.org/10.1016/j.jpba.2018.09.052] [PMID: 30312887]

[223]
Mohamed, D.; Elshahed, M.S.; Nasr, T.; Aboutaleb, N.; Zakaria, O. Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: Application to a pharmacokinetic study. BMC Chem.,  2019, 13(1), 82.
 [http://dx.doi.org/10.1186/s13065-019-0597-4] [PMID: 31384829]

[224]
Al Bratty, M.; Alhazmi, H.A.; Javed, S.A.; Lalitha, K.G.; Asmari, M.; Wölker, J.; El Deeb, S. Development and validation of LC-MS/MS method for simultaneous determination of metformin and four gliptins in human plasma. Chromatographia,  2017, 80(6), 891-899.
 [http://dx.doi.org/10.1007/s10337-017-3288-0]

[225]
Sengupta, P.; Bhaumik, U.; Ghosh, A.; Sarkar, A.K.; Chatterjee, B.; Bose, A.; Pal, T.K. LC-MS-MS Development and validation for simultaneous quantitation of metformin, glimepiride and pioglitazone in human plasma and its application to a bioequivalence study. Chromatographia,  2009, 69(11-12), 1243-1250.
 [http://dx.doi.org/10.1365/s10337-009-1056-5]

[226]
Polagani, S.R.; Pilli, N.R.; Gajula, R.; Gandu, V. Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. J. Pharm. Anal.,  2013, 3(1), 9-19.
 [http://dx.doi.org/10.1016/j.jpha.2012.09.002] [PMID: 29403791]

[227]
Reddy, S.; Ahmed, I.; Ahmad, I.; Mukhopadhyay, A.; Thangam, S. Development and Validation of a Method for Simultaneous Estimation of Metformin and Sitagliptin in Human Plasma by LC-MS-MS and Its Application in a Bioequivalence Study. J. Chromatogr. Sci.,  2015, 53(9), 1549-1556.
 [http://dx.doi.org/10.1093/chromsci/bmv055] [PMID: 25987553]

[228]
Nalawade, V.; Dixit, V.A.; Vora, A.; Zade, H. Development and validation of an LC-MS/MS method for simultaneous determination of canagliflozin and metformin HCl in rat plasma and its application. Curr. Pharm. Anal.,  2020, 16(6), 752-762.
 [http://dx.doi.org/10.2174/1573412915666190312161823]

[229]
Hamdan, I.I.; Jaber, A.K.B.; Abushoffa, A.M. Development and validation of a stability indicating capillary electrophoresis method for the determination of metformin hydrochloride in tablets. J. Pharm. Biomed. Anal.,  2010, 53(5), 1254-1257.
 [http://dx.doi.org/10.1016/j.jpba.2010.03.017] [PMID: 20395106]

[230]
Maher, H.M.; Abdelrahman, A.E.; Alzoman, N.Z.; Aljohar, H.I. Stability-indicating capillary electrophoresis method for the simultaneous determination of metformin hydrochloride, saxagliptin hydrochloride, and dapagliflozin in pharmaceutical tablets. J. Liq. Chromatogr. Relat. Technol.,  2019, 42(5-6), 161-171.
 [http://dx.doi.org/10.1080/10826076.2019.1590208]

[231]
Salim, M.; El-Enany, N.; Belal, F.; Walash, M.; Patonay, G. Simultaneous determination of sitagliptin and metformin in pharmaceutical preparations by capillary zone electrophoresis and its application to human plasma analysis. Anal. Chem. Insights,  2012, 7(1), ACI.S9940.
 [http://dx.doi.org/10.4137/ACI.S9940] [PMID: 22904611]

[232]
Capello, C.; Fischer, U.; Hungerbühler, K. What is a green solvent? A comprehensive framework for the environmental assessment of solvents. Green Chem.,  2007, 9(9), 927-934.
 [http://dx.doi.org/10.1039/b617536h]

[233]
Häckl, K.; Kunz, W. Some aspects of green solvents. C. R. Chim.,  2018, 21(6), 572-580.
 [http://dx.doi.org/10.1016/j.crci.2018.03.010]

[234]
Tobiszewski, M.; Namieśnik, J. Greener organic solvents in analytical chemistry. Curr. Opin. Green Sustain. Chem.,  2017, 5, 1-4.
 [http://dx.doi.org/10.1016/j.cogsc.2017.03.002]

[235]
Yabré, M.; Ferey, L.; Somé, I.; Gaudin, K. Greening reversed-phase liquid chromatography methods using alternative solvents for pharmaceutical analysis. Molecules,  2018, 23(5), 1065.
 [http://dx.doi.org/10.3390/molecules23051065] [PMID: 29724076]

[236]
Anastas, P.T. Green chemistry and the role of analytical methodology development. Crit. Rev. Anal. Chem.,  1999, 29(3), 167-175.
 [http://dx.doi.org/10.1080/10408349891199356]
Rights & Permissions Print Cite
Explore Articles
Open Access
Open Access Articles
DOI https://dx.doi.org/10.2174/1573412919666221025103613	Print ISSN 1573-4129
Publisher Name Bentham Science Publisher	Online ISSN 1875-676X
Current Pharmaceutical Analysis

Progress in Analytical Techniques for Remogliflozin Etabonate, Vildagliptin And Metformin Hydrochloride: A Recently, Approved FDC

Abstract Play Pause

Graphical Abstract

Abstract
